Insight Molecular Diagnostics Inc. — Director's Dealing 2019

Mar 18, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2019-03-14

Reporting Person: ANNETT WILLIAM (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-14	Option to Purchase Common Stock	$3.52	A	390000	Acquired	2029-03-13	Common Stock (390000)	Direct

Footnotes

F1: One quarter of the options shall vest upon the completion of one year of continuous service from the date of grant on March 14, 2019 and the balance shall vest in 36 equal monthly installments commencing on the first anniversary of the date of grant, based on continuous service on the applicable vesting date.